Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | CES2 | O00748 | 3/20 | 0.48 |
| ▸ | CES1 | P23141 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | ACHE | P22303 | 3/20 | 0.44 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12449035 | 0.83 | MAPT (0.32) | ALDH1A1CES2CES1LMNAHTT | |
| SCHEMBL893597 | 0.77 | HTT (0.55) | ALDH1A1CES2CES1LMNASMN1; SMN2 | |
| SCHEMBL21679926 | 0.77 | ALDH1A1 (0.52) | ALDH1A1CES2CES1LMNASMN1; SMN2 | |
| SCHEMBL20118491 | 0.77 | ALDH1A1 (0.52) | ALDH1A1CES2CES1LMNASMN1; SMN2 | |
| SCHEMBL94501 | 0.77 | ALDH1A1 (0.52) | ALDH1A1CES2CES1LMNASMN1; SMN2 | |
| SCHEMBL4412916 | 0.77 | HTT (0.55) | ALDH1A1CES2CES1LMNASMN1; SMN2 | |
| SCHEMBL17288381 | 0.77 | ALDH1A1 (0.52) | ALDH1A1CES2CES1LMNASMN1; SMN2 | |
| SCHEMBL10282614 | 0.74 | ALDH1A1 (0.55) | ALDH1A1CES2CES1LMNASMN1; SMN2 | |
| SCHEMBL27641076 | 0.74 | MAPT (0.60) | ALDH1A1CES2LMNASMN1; SMN2ACHE | |
| SCHEMBL208701 | 0.74 | CES2 (0.50) | CES2CES1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183213-A2 | OPTICALLY ACTIVE (R)-ARYLOXYPROPIONIC ACID AMIDES AND HERBICIDAL COMPOSITION COMPRISING SAME | Kyung Nong Corporation (KR) | 2010-05-12 | — | — | EP | claimed |
| WO-2009005297-A2 | OPTICALLY ACTIVE (R)-ARYLOXYPROPIONIC ACID AMIDES AND HERBICIDAL COMPOSITION COMPRISING SAME | KYUNG NONG CORPORATION (KR) | 2009-01-08 | — | — | WO | claimed |
| CN-116917289-A | T-type calcium channel antagonists and uses thereof | 小利兰·斯坦福大学董事会 | 2023-10-20 | — | — | CN | disclosed |
| US-20160225998-A1 | CHARGE-TRANSPORTING MATERIAL AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2016-08-04 | — | — | US | disclosed |
| CN-103739440-B | (Z)-2-bromo-1-fluoro-aromatic olefin type compound, as well as synthesis method and use thereof | UNIV TONGJI | 2015-04-08 | — | — | CN | disclosed |
| CN-103739440-A | (Z)-2-bromo-1-fluoro-aromatic olefin type compound, as well as synthesis method and use thereof | UNIV TONGJI | 2014-04-23 | — | — | CN | disclosed |
| EP-1984340-B1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-06-27 | — | — | EP | disclosed |
| CN-101379036-B | Anthranilamide/2-amino-heteroarene carboxamide derivatives | HOFFMANN LA ROCHE | 2011-06-01 | — | — | CN | disclosed |
| US-7678818-B2 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. (US) | 2010-03-16 | — | — | US | disclosed |
| CN-101379036-A | Anthranilamide/2-amino-heteroarene carboxamide derivatives | HOFFMANN LA ROCHE (CH) | 2009-03-04 | — | — | CN | disclosed |
| EP-1984340-A1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-10-29 | — | — | EP | disclosed |
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | HOFFMANN-LA ROCHE INC. | 2007-09-20 | — | — | US | disclosed |
| WO-2007090752-A1 | ANTHRANILAMIDE/2-AMINO-HETEROARENE CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-16 | — | — | WO | disclosed |
| WO-2005007614-A1 | MONOAMINE OXIDASE INHIBITORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 6011 (US) | 2005-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219261-A1 | Anthranilamide and 2-amino-heteroarene-carboxamide compounds | AADAT, AAAS, AADAC | ALDH1A1 1414/4885CES2 656/4885CES1 1471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.